Niaid clinical products center (CPC)
Active Definitive Contract Awarded Last action
- Contract number
- 75N93026C00003
- Awardee
-
Eminent Services Corp UEI C4PUY1BKHP59
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,634,911
Award facts
- Opportunity
-
- Niaid clinical products center (CPC) Pre-Solicitation · 75N93024R00018 · Posted Jul 9, 2024
- Contract value 11% obligated
-
- $3,634,911.00 Current, with exercised options
- $32,946,769.00 Potential, with all options
- Completion date 8% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $173,879 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,461,032 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $32.9 million definitive contract to Eminent Services Corp on April 1, 2026, for pharmacy and pharmaceutical oversight of NIAID and NIH-funded clinical trials under a cost-plus-fixed-fee pricing structure, with an ultimate completion date of March 31, 2033.
Eminent Services Corp is a minority-owned, Subcontinent Asian American-owned service provider based in Frederick, MD, which is also the place of performance. The contract covers study product management, regulatory document maintenance, Drug Master File co-submissions, product stability studies, clinical sample testing, and related services. The originating solicitation, posted July 9, 2024, was open to small businesses on a non-set-aside basis and identified the prior FY 2019 pharmacy support contract as the predecessor effort.
The contract is structured as a level-of-effort engagement with a base of approximately ten full-time equivalents per year and options for increased effort up to five times per contract year. The base period runs through March 31, 2027, followed by six optional annual extensions extending the potential performance window through March 31, 2033. SCI-reported invoicing across Eminent's prime service contracts from FY2022 through FY2024 totaled $10.5 million, with median government-paid hourly rates of approximately $170 per hour for prime contract labor. The vendor performs substantially all work in-house with zero sub-hours reported across its prime contracts.
Quick answers
Who was awarded contract 75N93026C00003?
75N93026C00003 was awarded to Eminent Services Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 1, 2026.
How much is contract 75N93026C00003 worth?
The government has obligated $3,634,911 on 75N93026C00003. Its potential value, with all options, is $32,946,769.
Was contract 75N93026C00003 competed?
The extent of competition for 75N93026C00003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award